Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Barrett Esophagus 13Esophageal Neoplasms 7Rectal Neoplasms 6Colorectal Neoplasms 6Adenocarcinoma Of Esophagus 6Nasopharyngeal Carcinoma 5Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Polyps 3Lung Neoplasms 3Precancerous Conditions 2Pathologic Complete Response 2Hyperplasia 2Gastroesophageal Reflux 2Colorectal Neoplasms, Hereditary Nonpolyposis 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Adenomatous Polyposis Coli 2Adenocarcinoma 2Urogenital Neoplasms 1Upper Tract Urothelial Carcinoma 1Thyroid Neoplasms 1Stomach Ulcer 1Stomach Diseases 1Recurrence 1Polyposis, Gastric 1Ovarian Neoplasms 1Nasopharyngeal Neoplasms 1Metaplasia 1

Interventions

Rituximab 4Etoposide 4Cyclophosphamide 4Vincristine 3Prednisone 3Doxorubicin 3liposomal doxorubicin 2varlilumab 1prednylidene 1pomalidomide 1fialuridine 1etoposide phosphate 1deltacortene 1Vorinostat 1Ultrasonography 1Salvia hispanica seed extract 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1Lenalidomide 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Endoscopy 1Electrocardiography 1Echocardiography 1Disulfides 1Cytarabine 1Carmustine 1CT-P10 1Bronchoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lymphoma, Primary Effusion × Endoscopy × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡